Dave Latshaw II predicts how AI might affect organizations of different sizes in biopharma and explains the various ways BioPhy is using...

He provides an in-depth discussion on this week's uniQure data, and upcoming data from Lexeo. Plus, comments on Alnylam, Dyne,...

Noubar Afeyan describes some areas that he sees the funding being deployed, his take on the current state of biotech, the IPO market,...

Alex Thompson gives his general take on I&I and comments on argenx, Immunovant, Ascendis, Celldex, Third Harmonic, Apogee, Spyre,...

Ilan Zipkin of Breakout Ventures says his firm looks at how cell therapies can be augmented with other technologies to help them succeed.

Founding Managing Director Adrien Cohen describes how this $30M fund has been structured, what typical investments will look like, and...

James Guest describes a recent clinical trial success using electrical stimulation of the cervical spinal cord, and also discusses best...

Brian Skorney gives his take on biotech and discusses Sarepta, Lexeo, Gilead, Mirum, Amgen, Vertex, Neurocrine, and Applied Therapeutics.

Chris Hollowood gives his take on biotech, the UK, portfolio companies iOnctura, Yellowstone Biosciences, and Spur Therapeutics...

Luca Issi gives his take on the sector and discusses news regarding Moderna, Caribou, Ultragenyx, Biomarin, Alnylam, Lexeo, and Wave Life...

Amy Brown will be covering biotech news and research in the London-Oxford-Cambridge triangle area for BiotechTV.

Salim Syed gives his take on Cytokinetics, BridgeBio, Enliven, Vaxcyte, and Wave Life Sciences.

Pete O'Heeron makes the case for fibroblasts and describes FibroBiologics's clincal MS program and upcoming ones for diabetic wound care...

We summarize BiotechTV's coverage of the conference including Enhertu, bispecific antibodies, the Summit news, and Moderna's highly...

Alaa Halawa introduces us to Mubadala Capital, describes what type of investments it looks for, and gives his take on the current...

Juergen Eckhardt describes how this strategic impact investing arm works within Bayer, the types of investments they look for and have...

Madeleine gives her take on data from Caribou, Summit, Daiichi Sankyo, GSK, Abbvie, and more.

Paul Rennert talks about the first four patients who have been dosed in Aleta's clinical trial, as well as previewing targets such as...

From McCormick Place, Jacob Plieth previews key data from Merus, Summit, Iovance, Caribou, AstraZeneca, GSK, Gilead, and more.

From a pre-ASCO event in Chicago, John Flavin describes how Portal invests in startups while giving them fully equipped lab space to work...